{
    "clinical_study": {
        "@rank": "48454", 
        "arm_group": {
            "arm_group_label": "Tapentadol", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "To find out if a drug called tapentadol administered by mouth safely relieves pain in\n      children.  Look at the amount of tapentadol in the blood after a single oral dose.\n\n      Tapentadol oral solution for children is still being tested and is not yet registered.\n      Tapentadol tablets are effective in treating both acute and chronic pain in adults. This\n      trial will help to understand how tapentadol oral solution works in children."
        }, 
        "brief_title": "Pharmacokinetic, Efficacy and Safety Study of Tapentadol Oral Solution in Children With Postoperative Pain", 
        "completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "condition": [
            "Postoperative Pain", 
            "Acute Pain"
        ], 
        "condition_browse": {
            "mesh_term": "Pain, Postoperative"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  A maximum body weight of 85.0 kg\n\n          -  A minimum body weight of 10 kg for participants aged 2 years to less than 3 years\n             old.\n\n          -  If female and post-menarchal, or 12 years or older, the subject has a negative urine\n             pregnancy test within 24 hours before surgery\n\n          -  Having completed either dental surgery or tonsillectomy with or without adenoidectomy\n             surgery (age group 6 to 17 years of age)\n\n          -  Having completed ear, nose, or throat surgery (including but not limited to\n             tonsillectomy (age group 2 to less than 3 years of age)\n\n          -  Participant aged 6 to less than 18 years has a post-operative pain intensity score\n             greater than or equal to 4 on the Color Analog Scale (CAS) as a result of the\n             surgical procedure or the participant has a pain level that the usual standard of\n             care following the surgical procedure (which reliably produces moderate to severe\n             pain) requires opioid treatment\n\n          -  Participant aged 2 years to less than 6 years has a pain level following a surgical\n             procedure that reliably produces moderate to severe pain, for which the usual\n             standard of care requires opioid treatment.\n\n          -  Participant is alert, orientated, and able to follow commands and complete the\n             post-operative required procedures\n\n        Exclusion Criteria:\n\n          -  History of brain injury\n\n          -  Clinically relevant abnormal ECG\n\n          -  Clinically unstable vital signs and/or a saturation of oxygen saturation (SpO2) less\n             than 93%.\n\n          -  Clinically relevant abnormal values for clinical chemistry, hematology, or urinalysis\n             at enrollment\n\n          -  Body temperature above 38.5\u00b0C within 48 hours prior to dosing"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "17 Years", 
            "minimum_age": "2 Years"
        }, 
        "enrollment": {
            "#text": "86", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 6, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01729728", 
            "org_study_id": "KF5503/68"
        }, 
        "intervention": {
            "arm_group_label": "Tapentadol", 
            "description": "Tapentadol oral solution single dose (1mg/kg body weight)", 
            "intervention_name": "Tapentadol", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Tonsillectomy", 
            "Dental surgery", 
            "Ear surgery", 
            "Nose surgery", 
            "Throat surgery"
        ], 
        "lastchanged_date": "March 4, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Salt Lake City", 
                    "country": "United States", 
                    "state": "Utah", 
                    "zip": "84124"
                }, 
                "name": "Jean Brown Research"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Open-label Evaluation of the Pharmacokinetic Profile, Safety, and Efficacy of Tapentadol Oral Solution for the Treatment of Post-surgical Pain in Children and Adolescents Aged From 2 Years to Less Than 18 Years.", 
        "overall_official": {
            "affiliation": "Gr\u00fcnenthal GmbH", 
            "last_name": "Study Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Pharmacokinetic profile of tapentadol after a single dose of tapentadol oral solution in children and adolescents age 2 to less than 18 years.", 
            "safety_issue": "No", 
            "time_frame": "15 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01729728"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from baseline of physical examination", 
                "safety_issue": "Yes", 
                "time_frame": "15 hours"
            }, 
            {
                "measure": "Change from baseline of ECG", 
                "safety_issue": "Yes", 
                "time_frame": "15 hours"
            }, 
            {
                "measure": "Change from baseline in safety laboratory", 
                "safety_issue": "Yes", 
                "time_frame": "15 hours"
            }, 
            {
                "measure": "Change from baseline of respiratory rate, blood pressure and heart rate", 
                "safety_issue": "Yes", 
                "time_frame": "15 hours"
            }, 
            {
                "measure": "Change from baseline in oxygen saturation", 
                "safety_issue": "Yes", 
                "time_frame": "15 hours"
            }, 
            {
                "measure": "Number of patients with adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "15 hours"
            }, 
            {
                "measure": "Number and intensity of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "15 hours"
            }, 
            {
                "measure": "Change from baseline in Pain intensity", 
                "safety_issue": "No", 
                "time_frame": "15 hours"
            }
        ], 
        "source": "Gr\u00fcnenthal GmbH", 
        "sponsors": {
            "collaborator": {
                "agency": "Janssen Research & Development, LLC", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Gr\u00fcnenthal GmbH", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}